These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9222552)

  • 1. Interaction of a new bis-indol derivative, KAR-2 with tubulin and its antimitotic activity.
    Orosz F; Kovács J; Löw P; Vértessy BG; Urbányi Z; Acs T; Keve T; Ovádi J
    Br J Pharmacol; 1997 Jul; 121(5):947-54. PubMed ID: 9222552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New semisynthetic vinca alkaloids: chemical, biochemical and cellular studies.
    Orosz F; Comin B; Raïs B; Puigjaner J; Kovács J; Tárkányi G; Acs T; Keve T; Cascante M; Ovádi J
    Br J Cancer; 1999 Mar; 79(9-10):1356-65. PubMed ID: 10188876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction of a new anti-tumour drug, KAR-2 with calmodulin.
    Orosz F; Vértessy BG; Salerno C; Crifo C; Capuozzo E; Ovádi J
    Br J Pharmacol; 1997 Jul; 121(5):955-62. PubMed ID: 9222553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro.
    Jordan MA; Himes RH; Wilson L
    Cancer Res; 1985 Jun; 45(6):2741-7. PubMed ID: 3986806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique pharmacology of KAR-2, a potential anti-cancer agent: absorption modelling and selective mitotic spindle targeting.
    Gonzalez-Alvarez I; Gonzalez-Alvarez M; Oltra-Noguera D; Merino V; Tõkési N; Ovádi J; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):11-9. PubMed ID: 19028571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-resistance of cultured murine leukemia vincristine-resistant P388 cells to vinblastine, vindesine, and bis (N-ethylidene vindesine) disulfide, disulfate.
    Wilkoff LJ; Dulmadge EA
    J Natl Cancer Inst; 1982 Jun; 68(6):1023-6. PubMed ID: 6953266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
    Lobert S; Vulevic B; Correia JJ
    Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estramustine depolymerizes microtubules by binding to tubulin.
    Dahllöf B; Billström A; Cabral F; Hartley-Asp B
    Cancer Res; 1993 Oct; 53(19):4573-81. PubMed ID: 8402630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of microtubule-phosphofructokinase complex: specific effects of MgATP and vinblastine.
    Vértessy BG; Kovács J; Löw P; Lehotzky A; Molnár A; Orosz F; Ovádi J
    Biochemistry; 1997 Feb; 36(8):2051-62. PubMed ID: 9047303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-calmodulin potency of indol alkaloids in in vitro systems.
    Molnár A; Liliom K; Orosz F; Vértessy BG; Ovádi J
    Eur J Pharmacol; 1995 Oct; 291(2):73-82. PubMed ID: 8566178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
    Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
    Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
    Lobert S; Frankfurter A; Correia JJ
    Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-allelic suppression of a mutation that stabilizes microtubules and confers resistance to colcemid.
    Wang Y; Veeraraghavan S; Cabral F
    Biochemistry; 2004 Jul; 43(28):8965-73. PubMed ID: 15248754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microtubule disruption induced in vivo by alkylation of beta-tubulin by 1-aryl-3-(2-chloroethyl)ureas, a novel class of soft alkylating agents.
    Legault J; Gaulin JF; Mounetou E; Bolduc S; Lacroix J; Poyet P; Gaudreault RC
    Cancer Res; 2000 Feb; 60(4):985-92. PubMed ID: 10706114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The structure of the complex of calmodulin with KAR-2: a novel mode of binding explains the unique pharmacology of the drug.
    Horváth I; Harmat V; Perczel A; Pálfi V; Nyitray L; Nagy A; Hlavanda E; Náray-Szabó G; Ovádi J
    J Biol Chem; 2005 Mar; 280(9):8266-74. PubMed ID: 15596444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
    Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
    Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of A-105972, an antineoplastic agent.
    Wu-Wong JR; Alder JD; Alder L; Burns DJ; Han EK; Credo B; Tahir SK; Dayton BD; Ewing PJ; Chiou WJ
    Cancer Res; 2001 Feb; 61(4):1486-92. PubMed ID: 11245455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
    Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
    Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative activity and mechanism of action of DZ-3358, a novel pyrimidinyl pyrazole derivative.
    Iwahana M; Ochi Y; Ejima A
    Anticancer Res; 2000; 20(2A):785-92. PubMed ID: 10810355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis induction via microtubule disassembly by an antitumour compound, pironetin.
    Kondoh M; Usui T; Nishikiori T; Mayumi T; Osada H
    Biochem J; 1999 Jun; 340 ( Pt 2)(Pt 2):411-6. PubMed ID: 10333483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.